Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:01:22.265Z.
Calculation as of: 2026-10-06T22:01:22.265Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fe921af54d6420969180622b7fbdd7ef934f73e64ffcc47ddb287d73eacb5931
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioVie Inc. (BIVI) | $10.86M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.83M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $10.94M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.00M | N/A | N/A | N/A | N/A |
| Lisata Therapeutics, Inc. (LSTA)vs › | $11.02M | N/A | 2.09 | 2.09 | 2.09 |
| Pluri Inc. (PLUR)vs › | $10.68M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.08M | N/A | 2.43 | 2.43 | 2.43 |
| VistaGen Therapeutics, Inc. (VTGN)vs › | $11.12M | N/A | N/A | N/A | N/A |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $10.45M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $11.36M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$1.44
Forward EPS (Est.)
$-0.63
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
